Anixa Biosciences Inc (ANIX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.28+7.19%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ANIX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
ANIX — litigation filed
Dated 2026-02-09
Regulation FD Disclosure. On February 9, 2026, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that encouraging patient survival data had been observed in its ovarian cancer CAR-T therapy Phase 1 clinical trial and that regulatory approval had been granted enabling dose escalation in the trial beyond the doses set forth in the original trial protocol. The press release is furnished as Exhibit 99.1 hereto Statements that are not historical fact m…
Why it matters: If healthcare sector growth speeds up, it could help Anixa's performance. It shows a stronger market environment.
Supportive ifHealthcare sector revenue growth rises above 10% year over year.
Worry ifHealthcare sector revenue growth stays below 9% year over year.
Why it matters: The earnings report will show how Anixa is doing financially and its future.
Watch forAnixa shares its next earnings date and gives updates on revenue and costs.
Also watch forAnixa delays or fails to announce its next earnings date.
Why it matters: Updates on trials could signal progress and investor confidence. It can impact stock sentiment.
Supportive ifManagement announces new trial results or plans in a press release.
Worry ifNo updates on trials or delays in planned trials.
Why it matters: Updates on financials can show if the company is improving. It affects investor trust.
Watch forAnixa shows smaller losses than last quarter.
Also watch forAnixa shows bigger losses than last quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$246 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $571 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,498 loss on $10,000 · 55.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Revenue growth trends affect investor confidence and funding for R&D. A drop signals potential issues.
Worry ifRevenue growth reported below the median for the sector.
Less concerning ifRevenue growth remains above the median for the sector.